GB201106750D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201106750D0
GB201106750D0 GBGB1106750.1A GB201106750A GB201106750D0 GB 201106750 D0 GB201106750 D0 GB 201106750D0 GB 201106750 A GB201106750 A GB 201106750A GB 201106750 D0 GB201106750 D0 GB 201106750D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
compounds
therapy
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1106750.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Priority to GBGB1106750.1A priority Critical patent/GB201106750D0/en
Publication of GB201106750D0 publication Critical patent/GB201106750D0/en
Priority to EP16197070.2A priority patent/EP3168213B1/en
Priority to ES12718620.3T priority patent/ES2615238T3/es
Priority to PCT/EP2012/057113 priority patent/WO2012143415A1/en
Priority to EP12718620.3A priority patent/EP2699551B1/en
Priority to JP2014505612A priority patent/JP5905075B2/ja
Priority to US14/111,625 priority patent/US8993554B2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1106750.1A 2011-04-21 2011-04-21 Novel compounds Ceased GB201106750D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1106750.1A GB201106750D0 (en) 2011-04-21 2011-04-21 Novel compounds
EP16197070.2A EP3168213B1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
ES12718620.3T ES2615238T3 (es) 2011-04-21 2012-04-19 Derivados de tetrahidroquinolinas como inhibidores de bromodominio
PCT/EP2012/057113 WO2012143415A1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
EP12718620.3A EP2699551B1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
JP2014505612A JP5905075B2 (ja) 2011-04-21 2012-04-19 ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体
US14/111,625 US8993554B2 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1106750.1A GB201106750D0 (en) 2011-04-21 2011-04-21 Novel compounds

Publications (1)

Publication Number Publication Date
GB201106750D0 true GB201106750D0 (en) 2011-06-01

Family

ID=44147342

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1106750.1A Ceased GB201106750D0 (en) 2011-04-21 2011-04-21 Novel compounds

Country Status (6)

Country Link
US (1) US8993554B2 (https=)
EP (2) EP2699551B1 (https=)
JP (1) JP5905075B2 (https=)
ES (1) ES2615238T3 (https=)
GB (1) GB201106750D0 (https=)
WO (1) WO2012143415A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106743D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
US9050346B2 (en) 2013-03-11 2015-06-09 Abbvie Inc. Bromodomain inhibitors
MX2015012158A (es) 2013-03-11 2015-12-01 Abbvie Inc Inhibidores de bomodominio tetraciclicos fusionados.
HUE043568T2 (hu) 2013-03-14 2019-08-28 Glaxosmithkline Ip No 2 Ltd 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規の置換された二環式化合物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規キナゾリノン
RU2720237C2 (ru) * 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN110627770A (zh) * 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9142676B2 (en) 2013-12-30 2015-09-22 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor liner of semiconductor device
HUE041546T2 (hu) 2014-01-09 2019-05-28 Orion Corp Biciklusos heterociklusos származékvegyületek mint bromo doméninhibitorok
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
JP6759514B2 (ja) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブNuevolution A/S ブロモドメインに対して活性な化合物
BR112017004580A2 (pt) 2014-09-12 2018-01-23 GlaxoSmithKline Intellectual Property composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Betタンパク質阻害剤として用いるための三環式複素環化合物
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
WO2018111805A1 (en) * 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
US11629152B2 (en) * 2018-03-30 2023-04-18 Kyowa Kirin Co., Ltd. Compound with anticancer activity
US12522587B2 (en) 2018-05-04 2026-01-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
UY39276A (es) 2020-06-19 2022-01-31 Bayer Ag Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones.
WO2022129190A1 (en) 2020-12-18 2022-06-23 Bayer Aktiengesellschaft (hetero)aryl substituted 1,2,4-oxadiazoles as fungicides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
US20100041891A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
WO2010074807A1 (en) * 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
WO2010111626A2 (en) * 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
GB0919431D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
WO2011054851A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
EP3168213B1 (en) 2018-08-01
EP2699551A1 (en) 2014-02-26
ES2615238T3 (es) 2017-06-06
US8993554B2 (en) 2015-03-31
EP3168213A1 (en) 2017-05-17
WO2012143415A1 (en) 2012-10-26
US20140031336A1 (en) 2014-01-30
JP5905075B2 (ja) 2016-04-20
JP2014511892A (ja) 2014-05-19
EP2699551B1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
GB201106750D0 (en) Novel compounds
GB201106743D0 (en) Novel compounds
GEP20186816B (en) Anty il-36r antybodies
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
ZA201406168B (en) Immunoconjugates, compositions containing them and use
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
IL232113A (en) Boron-containing compounds, pharmaceuticals containing them and their use in inhibiting arginase
PH12014502406B1 (en) Anti-il-23p19 antibodies
PH12014501991B1 (en) Phenicol antibacterials
ZA201501394B (en) Coated pharmaceutical composition containing regorafenib
IN2014DN06104A (https=)
IL235414A (en) The history of pyrolotriazinone, their preparation and their pharmaceutical preparations
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MY161601A (en) Films and compositions comprising the same
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12015501302A1 (en) Compositions comprising vortioxetine and donepezil
MY165088A (en) Pharmaceutical compositions comprising alisporivir
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX356102B (es) Compuestos y métodos para tratar leucemia.
EP2930175A4 (en) NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF
MX2013008559A (es) Derivados de leptina.
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)